Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enterovirus A71 structural proteins are four viral proteins (VP1, VP2, VP3, and VP4) that assemble to form the icosahedral capsid of Enterovirus A71 (EV-A71), a member of the Picornaviridae family[1][2][3][5][6]. These proteins result from cleavage of the P1 polyprotein precursor and form a single protomer; five protomers make a pentamer, and 12 pentamers constitute a complete viral capsid. VP1, VP2, and VP3 are exposed on the virion surface and are involved in binding host cell receptors and are the main targets of neutralizing antibodies. VP4 is located internally, lining the inner capsid surface. Drugs and vaccines targeting these structural proteins, especially VP1, are major approaches for antiviral intervention and immunization against EV-A71, which is responsible for outbreaks of hand, foot, and mouth disease and serious neurological disease in children[1][3][5].
- Inhibition of viral capsid dynamics or uncoating - Blockage of receptor attachment or entry
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enterovirus A71 structural protein (EV-A71 structural protein).